Tratamiento con icotinib en pacientes con cancer de pulmón de células no pequeñas .

1. T O M Á S C O R R E A G .
K A R E N C A N O C .
M E D I C I N E S T U D E N T S

2. A body has about a thousand, billion cells, which,
when healthy, are indefinetely renewed. Some of
these cells die every day and are replaced by new
identical cells.

3. On some occassions a normal cell undergoes an
alteration or errors due to numerous (exogenous)
factors, such as:

4. These alterations or errors create a change in the
DNA structure, leading to mistakes in the replication
process.

5. There are endogenous causes that produce cancer;
each person has hereditary factors (genes) that can
lead to cancer. These genes are know as
oncogenes.

7. When the cancerous cells proliferate at an
abnormal rate, and there is a majority of cancerous
(new) cells, the cellular mass is called a tumor.

8. The immune system protects us from various abnormal agents or
cells.
But in cancer, there are multiple factors that affect the function of the
immune system:
• Tumoral cells reduce the expression of antigens in their
membranes.
• Secretion of substances that reduce the function of the immune
system.
• Tumors can grow without producing inflammation

9. It is a large group of diseases that are
characterized by an abnormal growth of
cell and the dissemination of these cells.

10. Carcinomas Sarcomas Lymphomas Leukemia

11. LUNG NON SMALL CELL CARCINOMA
Is the most common lung cancer
The principal cause is the exposure to tobacco smoke.

12. There are three forms:
-adenocarcinoma
-squamous cell carcinoma
-large cell carcinoma

13. Adenocarcinoma: cells that line the alveoli
Squamous cell carcinoma: in squamous cells
Large cell carcinoma: begin in several types of large cells

14. Palliative care
Surgery
Chemotherapy
Radiation therapy

15. USED PERSONALIZED
BIOMARKERS TO MONITOR
DISEASE PROGRESSION IN
ADVANCED NON-SMALL-CELL
LUNG CANCER PATIENTS
THAT ARE TREATED WITH
ICOTINIB

16. Icotinib Hydrochloride (BPI-2009H), or Icotinib, is a highly selective,
first generation epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI). EGFR is an oncogenic driver and patients with
somatic mutations, particularly an exon 19 deletion or exon 21 L858R
mutation, within the tyrosine kinase domain have activating mutations
that lead to unchecked cell proliferation. Overexpression of EGFR
causes inappropriate activation of the anti-apoptotic Ras signaling
pathway, found in many different types of cancer. Icotinib is a
quinazoline derivative that binds reversibly to the ATP-binding-site of
the EGFR protein, preventing completion of the signal transduction
cascade.

17. Icotinib en dosis de
150 mg 2 veces al
día o 125mg 3
veces al día
Seguido por
un periodo de
3 dias
Progreso de
enfermedad
Inexplicable
toxicidad
Rechazo al
tratamiento
Antes del
tratamient
o
En tratamiento
después de un
periodo de ayuno de
10 horas en la noche

18. Complejo IIRPCs (
inmunoinflammation-
related protein
complexes)
9
MUESTRA
S
1
CONTRO
L
Mezcla
aleatoria
del
plasma
de 5
pacientes
Patrones de enfermedad
encontrados:
a1,a2,a3,a4,a5,b1,b2,b3,b
4,b5,b6,d1,d2,d3,e1,e2 y
e3
Complejo TRPC (
transferrin-related
protein complex)

19. IIRPCs immuno inflammation-related protein complexes are associated with
disease status.
Epidermal growth factor receptor, the EGFR belongs to the family of tyrosine
kinase receptors, EGFR plays a fundamental role in tumor development.

20. Immunoglobulin G1
-Interferes with the activation of the T-lymphocytes
-Participate in the answer antigen A
-To fix the complement
-Joins to receptors FC in phagocytic cells
IGA
-This is in mucus
-Is the first responder
-Hinder the entrance of microorganism into the organism

21. Haptoglobin
-This is fixed to the breakdown of hemoglobin.
-Increases when the red blood cells are died.
-recycle the components of the hemoglobin.
Complement components
-C3, C4: inflammation, increases in cancer.
-C5: the first component of the complement of attack to membrane.
-C7: component of attack to membrane.

22. Factor H
-Protein regulatory of the complement
Transferrin
-Transports iron to plasma to the erythroblasts that are in marrow
Apolipoprotein A1
-This are present in cholesterol HDL

23. Los patrones a, b y
c fueron recogidos
antes de iniciar el
tratamiento.
• 19 pacientes con Patrón
A
• 8 pacientes con Patrón B
• 4 pacientes con Patrón
C

24. Complejo TRPC
Común en los 5
patrones ( a ,b ,c ,d y
e) y el de mayor
intensidad.
Sus componentes fueron
identificados usando
espectrofotometría
Ig-G1, Ig-A1, Haptoglobina, Complemento componente 3-4ª-5-
7, Factor de complemento H, Transferrina y Apolipoproteina A-
1.

25. Complejo TRPC
No asociado con el patrón de IIRPCs,
mutaciones en EGFR, dosis de
medicamento, fumar, etapas,
características histológicas, edad y
sexo.
Valor de TRPC tuvo
una estable expresión
durante el tratamiento
con icotinib
Usado como
referencia
interna para
la
cuantificación
de IIRPCs

26. 7 Pacientes con patrón a cambiaron a patrón d, y 2 Pacientes con patrón b
cambiaron a patrón e durante el tratamiento con icotinib, luego volvieron a
su patrón original ya que generaron resistencia al medicamento, toxicidad o
por el progreso de la enfermedad.
Valle
formado
por el
cambio de
patrón.

27. PATIENTS

28. RESULTADOS

29. 1 paciente respuesta completa
8 respuesta parcial
19 estable
3 progreso

30. References What did they say? Agree with
the article?
Wang YY, Song
GG, Wang YM,
Qui L, Qin XZ, Liu
H
• The measurement
of the IIRPCs level
is convenient
using the
optimized native
polyacylamide gel.
• Elevated serum
levels of
circulating
inmunoinflammati
on-related protein
complexes are
associated with
cancer and
disease
progression.

31. AUTHOR THEORY AGREE
Dahabreh IJ, Linardou H, Kosmidis P,
Bafaloukos D, Murray S.
O'Byrne K, Paz-Ares L, Pereira JR,
von Pawel J, Ramlau R, Storkel S.
Onitsuka T, Uramoto H, Nose N,
Takenoyama M, Hanagiri T, Sugio K.
Activation of the EGFR pathway has been
implicated in NSCLC tumorigenesis, and EGFR
has become an important target for the
development of personalized therapy.
However, acquired drug-resistance always
occurred during the treatment. Recently,
several molecular biomarkers such as EGFR
expression and EGFR mutations have been
Investigated as potential indicators of the
treatment response to EGFRTKIs in NSCLC.
Agree

32. 1. La actividad me pareció una buena experiencia para aprender a como
presentar de una manera adecuada un seminario sobre un respectivo articulo.
2. La actividad sirvió mucho para practicar nuestro ingles y poder aprender
nueva terminología respecto al área de biología molecular y medicina

33. Conocer la actividad molecular de un tumor puede dar indicios de su
comportamiento y formas de evitar su crecimiento.
Una gran problemática a la hora de realizar cualquier tipo de tratamiento es
que el organismo genere resistencia.

34. REFERENCIAS
Bioinformatics of Non Small Cell Lung Cancer and the Ras Proto-Oncogene
By Amita Kashyap, D. Bujamma, Naresh Babu M
Elevated serum levels of circulating immunoinflammation-related protein complexes are associated with cancer.
Wang Y1, Song G, Wang Y, Qiu L, Qin X, Liu H, Li F, Wang X, Li F, Guo S, Zhang Y, Li Z.
Elevated serum levels of circulating immunoinflammation-related protein complexes are associated with cancer.
J. Proteome Res.
J Proteome Res 2014 Feb 17;13(2):710-9. Epub 2013 Dec 17.
Yanying Wang, Gaoguang Song, Yanmin Wang, Ling Qiu, Xuzhen Qin, Hui Liu, Fang Li, Xiaodong Wang,Fenjie
Li, Shuai Guo, Yaping Zhang, Zhili Li
Revista Habanera de Ciencias Médicas versión On-line ISSN 1729-519X Rev haban cienc méd v.9 n.2 Ciudad de La
Habana abr.-jun. 2010
Introducción a la inmunología humana By Leonardo Fainboim, Jorge Geffner
http://infoterbaru.zz.vc/info.php?q=cancer+research+uk+online+shop+online+shop+from+cancer+

35. MAPA CONCEPTUAL.